Pharmaceutical company intelligence

Shaigan Pharmaceuticals (Pvt) Ltd

Private pharmaceutical manufacturer · Rawalpindi · Pakistan

Rawalpindi-based pharmaceutical manufacturer focused on branded generic medicines, quality systems and international market expansion.

Sourced corporate profile Corporate identity fields are source-tracked; portfolio, price and competitor intelligence remains independently calculated by MedInfoBase.

Official website ↗ Official contact ↗

Evidence & freshness

What is sourced, and how recent is it?

Public-source corporate details

Latest regulatory-source observation23 Sep 2026Newest linked source record observed by MedInfoBase

Latest portfolio source check22 Sep 2026Latest source-check date across this published portfolio

Latest effective price date18 Aug 2026Newest effective date among published current price records

Corporate profile evidence5 sourcesCorporate source details checked 16 Aug 2026

Regulatory-source portfolio data and company-supplied/corporate profile fields are tracked separately. Company claim/verification status is separate from source quality. An unclaimed company can still have a fully official-source-observed portfolio.

Location intelligence

Company location

Google Maps

Location recorded

A sourced company location is recorded. Use the map link below for directions.

Open in Google Maps ↗

Intelligence snapshot

Portfolio at a glance

Not sales data · published MedInfoBase database view

Rx210public portfolio records represented

REG150unique registrations represented

IDX11indexed MedInfoBase presentations

SRC0additional source-observed presentations

R+0registry-only registrations

VER0registry-verified exact registrations

PKR198current validated price records

G74generic molecules in indexed catalogue

DF13dosage-form groups

TA17therapeutic areas

How to read these counts

RegistrationA unique regulatory registration number. One registration may have more than one strength/form/pack presentation.

PresentationA distinct medicine presentation, such as a particular strength, dosage form and pack.

IndexedA canonical MedInfoBase presentation that passed MedInfoBase identity and publication controls.

Source observedAn additional presentation observed in an official DRAP source but not counted as an indexed MedInfoBase presentation.

Registry onlyAn exact registry-verified registration not otherwise represented by an indexed or source-observed presentation.

Registry verifiedAn exact registration match found in an official DRAP registry source. This is evidence status, not a commercial ranking.

Data coverage

How complete is this profile?

Current price coverage94%

public portfolio presentations with a validated current price

Official-source coverage100%

products linked back to a source record

Unit-price parse coverage99%

priced packs safely normalized per unit

Comparable-market coverage90%

products with at least one like-for-like comparator

Therapeutic classification100%

products assigned to a broad therapeutic area

Visual intelligence

Downloadable company intelligence charts

Copy or download any chart as a presentation-ready PNG. Every exported chart keeps MedInfoBase attribution and the source company-profile URL.

Shareable intelligence

Therapeutic Portfolio Mix

Shows where the company portfolio is concentrated across broad therapeutic areas.

Portfolio distribution, not sales or market-share data.

Shareable intelligence

Dosage Form Portfolio

Shows how the company portfolio is distributed across tablets, capsules, injections, liquids and other forms.

Counts are product presentations, not production or sales volumes.

Shareable intelligence

Equivalent Price Position

Shows whether safely comparable products are below, near or above the peer median unit price.

This is price-position intelligence, not sales, demand or market-share data.

Shareable intelligence

Closest Portfolio Competitors

Highlights other manufacturers with the greatest generic overlap with this company portfolio.

Competitor ranking is based on shared generics in MedInfoBase, not commercial sales performance.

Portfolio intelligence

Therapeutic areas

Broad portfolio view

High-level clinical areas represented by this company’s current MedInfoBase portfolio.

Anti-infectives105 products · 53%

Reproductive & genitourinary13 products · 7%

Hematology & thrombosis13 products · 7%

Cardiovascular11 products · 6%

Endocrine & metabolic10 products · 5%

Gastrointestinal & hepatology9 products · 5%

Vitamins, minerals & nutrition8 products · 4%

Respiratory & allergy7 products · 4%

Pharmacological detail

Drug classes

More specific view

More specific classes derived from the canonical generic and preserved curated classifications.

Third-generation cephalosporins42 products · 21%

Antivirals13 products · 7%

Anticoagulants10 products · 5%

Antiparasitic medicines10 products · 5%

Antifungals9 products · 5%

Antidiabetic medicines9 products · 5%

Antimalarials9 products · 5%

Vitamins / minerals / hematinics8 products · 4%

Formulation footprint

Dosage forms

Tablet92 products

Injection54 products

Capsule15 products

Cream12 products

Syrup10 products

Suspension5 products

Drops2 products

Gel2 products

Sachet2 products

Lotion1 products

Ointment1 products

Pessary1 products

How MedInfoBase classifies the portfolio

MedInfoBase uses a two-level taxonomy. Therapeutic area is a broad portfolio category, while drug class is the more specific pharmacological or clinical class. Existing curated classifications are preserved. Blank records are assigned conservatively from the canonical generic name and, when available, ATC information. Multi-use medicines may be placed in a cross-therapeutic category rather than forced into a single indication.

Portfolio leaders

Deepest brand families

Ranked by registered presentations · not sales

#1 Celtis-1000Ceftriaxone 9presentations 1000 mg · Injection #2 Celtis-250Ceftriaxone 8presentations 250 mg · Injection #3 Celtis-500Ceftriaxone 7presentations 500 mg · Injection #4 SkabPermethrin 7presentations 5% w/w, 50 mg, 50 mg/g · Cream, Lotion #5 BexusLevofloxacin 6presentations 250 mg, 500 mg, 750 mg · Tablet #6 CeltisCeftriaxone 6presentations 1000 mg, 250 mg, 500 mg · Injection

Price intelligence

Unit-price positioning vs equivalent products

Same generic + strength + form + unit basis

Below market median7441% of comparable products

Near market median37within ±5% of median

Above market median6838% of comparable products

Lowest-price equivalents16ties included

Company median price position +0.0% relative to the median unit price of like-for-like equivalent products.

Most competitively positioned examplesProducts with at least 3 market comparators

Sygate 0.3 mgConjugated estrogens · Tablet · 30's PKR 3.72/tablet-89.9% vs market median Embex 10 mgRivaroxaban · Tablet · 4x7's PKR 67.23/tablet-87.8% vs market median Embex 10 mgRivaroxaban · Tablet · 10's PKR 70.03/tablet-87.3% vs market median Embex DS 20 mgRivaroxaban · Tablet · 4x7's PKR 118.65/tablet-86.7% vs market median Embex Forte 15 mgRivaroxaban · Tablet · 4x7's PKR 94.92/tablet-86.5% vs market median

How MedInfoBase calculates price position

Only current prices with safely interpretable pack quantities are used. A product is compared only with the same generic, same stated strength, same dosage form and a compatible unit basis such as tablet, capsule, mL or gram. These are database-derived price comparisons, not sales or market-share estimates.

Competitive landscape

Portfolio overlap

Companies sharing the largest number of generics with this portfolio. This measures product overlap, not commercial performance.

Nabiqasim Industries (Pvt) Ltd.,365 products · 118 generics 43shared generics TABROS PHARMA (PVT). LTD.179 products · 65 generics 37shared generics Pharmasol (Pvt) Ltd.257 products · 102 generics 36shared generics CCL Pharmaceuticals (Pvt.) Limited249 products · 99 generics 36shared generics Valor Pharmaceuticals219 products · 97 generics 36shared generics Neutro Pharma (Pvt.) Ltd.,210 products · 97 generics 36shared generics

Regulatory & price activity

Observed database signals

Indexed registration numbers140Distinct registrations among indexed, published, presentation-validated products only

Verified price observations378

Products with a verified price198

Products with multiple price observations180

Source records with multiple versions198

Latest portfolio source check22 Sep 2026

Latest effective price date18 Aug 2026

Latest source observation23 Sep 2026

These dates describe records observed by MedInfoBase. They should not be interpreted as product launch dates or sales activity.

Company medicine portfolio

Medicine portfolio

150 unique registration(s) · 11 indexed presentation(s)

This unified portfolio keeps three evidence lanes distinct: indexed MedInfoBase presentations, additional source-observed presentations, and registry-only registrations that are not otherwise represented. A registration number is not the same thing as a presentation, and source-observed rows are not counted as indexed. Source-only rows with a strength/form/pack contradiction remain visible as evidence but the conflicting field is held for normalization.

Intelligence filter: Therapeutic areaCardiovascular Clear intelligence filters

Brand	Generic	Strength	Form	Pack	Registration	Source-listed price	Unit price	Price position
Amlopin	Amlodipine	5 mg	Tablet	20's	019300	PKR 275.51	PKR 13.78/tablet	27% above median
Bisoprol	Bisoprolol fumarate	2.5 mg	Tablet	14's	121498	PKR 34.74	PKR 2.48/tablet	42% below median
Bisoprol	Bisoprolol fumarate	5 mg	Tablet	20's	121499	PKR 144.76	PKR 7.24/tablet	40% below median
Bisoprol	Bisoprolol fumarate	10 mg	Tablet	20's	121500	PKR 260.58	PKR 13.03/tablet	41% below median
Enaril	Enalapril	5 mg	Tablet	20's	026641	PKR 130.15	PKR 6.51/tablet	31% above median
Enaril	Enalapril	10 mg	Tablet	20's	026642	PKR 232.14	PKR 11.61/tablet	60% above median
N-Glycrin SR	Nitroglycerin	2.6 mg	Sustained-release tablet	30's	119088	PKR 209.62	PKR 6.99/tablet	35% below median
Remet-1.25	Ramipril	1.25 mg	Tablet	14x2's	057269	PKR 493.18	PKR 17.61/tablet	15% above median
Remet-2.5	Ramipril	2.5 mg	Tablet	14x2's	057268	PKR 863.07	PKR 30.82/tablet	19% above median
Remet-5	Ramipril	5 mg	Tablet	14x2's	057267	PKR 986.38	PKR 35.23/tablet	11% above median
Wetrex	Furosemide	50 mg	Tablet	20's	096497	PKR 118.93	PKR 5.95/tablet	No comparator

MedInfoBase company-intelligence methodology

This page is generated from MedInfoBase medicine, generic, company, price and official-source records. Unverified third-party discovery records are retained internally for coverage auditing and are not published as company registrations. Portfolio leaders are ranked by presentation depth, not sales. Price-position metrics are calculated from current official-source prices normalized to compatible units and compared only against like-for-like products with the same generic, stated strength and dosage form.

Not currently included: sales volume, revenue by brand, market share, prescription volume or best-selling rankings. MedInfoBase will display those only when supported by a defensible licensed, public or company-verified source.

Cite this record

Manufacturer record

MedInfoBase. (2026). Shaigan Pharmaceuticals (Pvt) Ltd — registered product portfolio in Pakistan [Data set]. MedInfoBase. Retrieved September 24, 2026, from https://medinfobase.com/company/shaigan-pharmaceuticals-pvt-ltd/

Download .RIS Download .BIB EndNote, Zotero, Mendeley, RefWorks

Records change over time. Please cite the access date so readers can locate the version you used.

Shaigan Pharmaceuticals (Pvt) Ltd

What is sourced, and how recent is it?

Company profile

Company location

Portfolio at a glance

How complete is this profile?

Downloadable company intelligence charts

Therapeutic Portfolio Mix

Dosage Form Portfolio

Equivalent Price Position

Closest Portfolio Competitors

Therapeutic areas

Drug classes

Dosage forms

Deepest brand families

Unit-price positioning vs equivalent products

Portfolio overlap

Observed database signals

Medicine portfolio

Cite this record